Cargando…
Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review
BACKGROUND: Metastatic triple-negative breast cancer (mTNBC), an aggressive histological subtype, has poor prognosis. Chemotherapy remains standard of care for mTNBC, although no agent has been specifically approved for this breast cancer subtype. Instead, chemotherapies approved for metastatic brea...
Autores principales: | Li, Claire H., Karantza, Vassiliki, Aktan, Gursel, Lala, Mallika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916124/ https://www.ncbi.nlm.nih.gov/pubmed/31842957 http://dx.doi.org/10.1186/s13058-019-1210-4 |
Ejemplares similares
-
Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer
por: Jiang, Di (Maria), et al.
Publicado: (2019) -
Triple-negative breast cancer: current perspective on the evolving therapeutic landscape
por: Mehanna, Joe, et al.
Publicado: (2019) -
Current landscape of personalized clinical treatments for triple-negative breast cancer
por: Zhang, Jun, et al.
Publicado: (2022) -
Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)
por: Lee, Jieun
Publicado: (2023) -
Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions
por: Hossain, Fokhrul, et al.
Publicado: (2021)